Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer

Journal of the American College of Surgeons

Volumn 197, Issue 6, 2003, Pages 955-963

  Morice, Philippe ^a   Dubernard, Gil ^a   Rey, Annie ^a   Atallah, David ^a   Pautier, Patricia ^a   Pomel, Christophe ^a   Lhommé, Catherine ^a   Duvillard, Pierre ^a   Castaigne, Damienne ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; PLATINUM; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OBSERVATION; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MORBIDITY; OVARY CANCER; PERITONEUM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGEON; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT THERAPY; CANCER INVASION; COMPARATIVE STUDY; DRUG ADMINISTRATION; EVALUATION; GYNECOLOGIC SURGERY; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0642333855     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2003.06.004     Document Type: Article

References (31)

1. Griffiths T.C., Parker L.M., Fuller A.F. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 63:1979;235-240.
2. Dauplat J., Le Bouëdec G., Pomel C., Kauffmann P. Chirurgie initiale des cancers epithéliaux avancés de l'ovaire. Ann Chir. 51:1997;1058-1068.
3. Michel G., De Iaco P., Castaigne D., et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaec Oncol. 18:1997;9-15.
4. Guidozzi F., Ball J.H. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 53:1994;326-330.
5. Shimada M., Kigawa J., Minagawa Y., et al. Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer. Am J Clin Oncol. 22:1999;481-484.
6. Lawton F.G., Redman C.W., Luesley D.M., et al. Induction (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced epithelial ovarian cancer. Obstet Gynecol. 73:1989;61-65.
7. Jacob J.H., Gershenson D.M., Morris M., et al. Induction chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 42:1991;146-150.
8. Lim J.T.W., Green J.A. Induction carboplatin and ifisfamide chemotherapy in inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol. 5:1993;198-202.
9. Redman C.W., Warwick J., Luesley D.M., et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol. 101:1994;142-146.
10. Onnis A., Marchetti M., Padovan P., Castellan L. Induction chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol. 17:1996;393-396.
11. Surwit E., Childers J., Atlas I., et al. Induction chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 6:1996;356-361.
12. Vergote I.B., De Wever I., Decloedt J., et al. Induction chemotherapy or primary debulking surgery in advanced ovarian carcinoma a retrospective analysis of 285 patients . Gynecol Oncol. 71:1998;431-436.
13. Schwartz P.E., Rutherford T.J., Chambers J.T., et al. Induction chemotherapy for advanced ovarian cancer Long-term survival . Gynecol Oncol. 72:1999;93-99.
14. Kayikcioglu F., Kose M.F., Boran N., et al. Induction chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer. 11:2001;466-470.
15. Kuhn W., Rutke S., Spathe K., et al. Induction chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 92:2001;2585-2591.
16. Ansquer Y., Leblanc E., Clough K., et al. Induction chemotherapy for unresectable ovarian carcinoma. Cancer. 91:2001;2329-2334.
17. Dotor E.M., Ponce J., Balaguen L., et al. Induction chemotherapy (NACT) in advanced ovarian cancer (AOC) experience of the Gynecologic-Oncology Unit . Proc ASCO. 21:2002;853.
18. Morice P., Brehier-Ollive D., Rey A., et al. Results of interval debulking surgery in advanced stage ovarian cancer An exposed-nonexposed study . Ann Oncol. 14:2003;74-77.
19. Van der Burgh M.E., Van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 332:1995;629-634.
20. Hacker N.F., Berek J.S., Lagasse L.D., et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 61:1983;413-420.
21. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of the diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 170:1994;974-980.
22. Eisenkop S.M., Friedman R.L., Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer A prospective study . Gynecol Oncol. 69:1998;103-108.
23. Eisenkop S.M., Spirtos N.M., Montag T.W., et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 47:1992;203-209.
24. Donato D., Angelides A., Irani H., et al. Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites. Gynecol Oncol. 44:1992;40-47.
25. Rose P.G., Nerenstone S., Brady M., et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease a Gynecologic Oncology Group study . Proc ASCO. 21:2002;802.
26. Morice P., Joulie F., Camatte S., et al. Lymph node involvement in epithelial ovarian cancer Analysis of 276 pelvic and para-aortic lymphadenectomies and surgical implications . Gynecol Oncol. 88:2003;202.
27. Leblanc E., Querleu D., Fazel A., et al. Decision laparoscopy in advanced ovarian cancer a series of 102 cases . Int J Gynecol Cancer. 13:(Suppl 1):2003;43.
28. Morice P., Viala J., Pautier P., et al. Port site metastasis after laparoscopic surgery for gynecological cancer. Report of 6 cases and surgical implications for prevention. J Reprod Med. 45:2000;837-840.
29. Marquette S., Amant F., Berteloot P., et al. Port site metastases are frequent after open laparoscopy in patients with advanced ovarian carcinoma, but do not influence the survival an analysis of 173 cases . Int J Gynecol Cancer. 13:(Suppl 1):2003;2.
30. Van Dam P.A., DeCloedt J., Tjalma W.A., et al. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer can the risk be reduced? Am J Obstet Gynecol. 181:1999;536-541.
31. Vergote I.B., De Wever I., Decloedt J., et al. Induction chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol. 27:2000;31-36.